Company Encyclopedia
View More
name
Ocean Biomedical, Inc.
OCEA.US
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company’s oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS). The company’s infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P.
1.936 T
OCEA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ocean Biomedical Inc. Faces Delisting as Nasdaq Upholds Decision to Remove Company's Securities

    Ocean Biomedical Inc. faces delisting from the Nasdaq following the Board of Directors' decision to uphold the removal of its securities. The company was informed on July 31, 2025, that its appeal was denied, making the Nasdaq Listing and Hearing Review Council's decision final. The delisting will proceed under Nasdaq and SEC rules. Despite this setback, Ocean Biomedical is continuing to develop its power and cryptocurrency strategies.

    Reuters·
    US
    OCEA
    0.00%
    Reuters·
    US
    OCEA
    0.00%

    Ocean Biomedical Inc. Faces Delisting from Nasdaq as Appeal is Denied by Listing Council

    Ocean Biomedical Inc. is facing delisting from Nasdaq as the Listing and Hearing Review Council has upheld the decision to suspend trading of its shares, effective April 24, 2025. The Nasdaq Hearings Panel initially decided on this action on April 22, 2025, and despite the company's appeal, the Listing Council affirmed the decision, marking a significant challenge for the company.

    Reuters·
    US
    OCEA
    0.00%
    Reuters·
    US
    OCEA
    0.00%

    Ocean Biomedical Inc. Files Amendment to 10-K Annual Report

    Ocean Biomedical Inc. has filed an amendment to its 10-K annual report for the fiscal year ending December 31, 2024. The filing is accessible via the provided link. This news brief was generated by Public Technologies (PUBT) using AI and is intended for informational purposes only, not as financial or legal advice. The original content was published via EDGAR by Ocean Biomedical Inc. on April 29, 2025.

    Reuters·
    US
    OCEA
    0.00%
    Reuters·
    US
    OCEA
    0.00%

    Ocean Biomedical has been granted patent rights in China for bispecific antibodies targeting CHI3L1 and PD1 to enhance tumor cell cytotoxicity.

    Ocean Biomedical, Inc. (NASDAQ: OCEA) based in Providence, R.I., revealed that the China National Intellectual Property Administration (CNIPA) has recently approved a patent for its novel bispecific antibodies that target CHI3L1 and PD1. These antibodies aim to improve T cell-mediated cytotoxicity against cancer cells, infectious diseases, and fibrosis. The announcement was made on March 28, 2025, marking a significant milestone for the company in the treatment of various diseases.

    Unusual Whales·
    US
    OCEA
    0.00%
    Unusual Whales·
    US
    OCEA
    0.00%

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    In Thursday's pre-market session, Soleno Therapeutics (SLNO) shares surged 38.8% to $67.98, while Ocean Biomedical (OCEA) rose 23.05% to $0.1. Other gainers included Edap TMS (EDAP) up 20.48% to $2.47, and XTL Biopharmaceuticals (XTLB) up 16.36% to $1.28. Conversely, OSR Holdings (OSRH) fell 21.9% to $2.96, Equillium (EQ) dropped 20.85% to $0.6, and Petros Pharma (PTPI) decreased 11.19% to $0.12. Overall, several health care stocks experienced significant movements in pre-market trading.

    Benzinga·
    US
    OCEA
    0.00%
    US
    XTLB
    -5.74%
    US
    EDAP
    +14.48%
    Benzinga·
    US
    OCEA
    0.00%
    US
    XTLB
    -5.74%
    US
    EDAP
    +14.48%
    © 2025 Longbridge｜Disclaimer